Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
1(20.0%)
Phase 3
1(20.0%)
5Total
Phase 1(3)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07294846Phase 1Completed

Drug Interaction Study on Linaprazan Glurate Capsules

Role: lead

NCT07107672Phase 1Completed

Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects

Role: lead

NCT07079540Phase 3Completed

The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis

Role: lead

NCT04531475Phase 2Completed

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

Role: lead

NCT04293965Phase 1Completed

Single-dose and Multiple-dose X842 Phase 1 Study

Role: lead

All 5 trials loaded